BRIDGEWATER, N.J. - (Business Wire)
Neurotez, Inc., a company developing therapies for Alzheimer’s disease, today announced that it has been selected as a
Featured Company for the 2008 MAC Conference. A Presentation will be held on Wednesday, December 3 by Chief Executive Officer, Dr. Nikolaos Tezapsidis on 2:45pm in Life Sciences Room 201ABC at the Pennsylvania Convention Center, Philadelphia, PA.
About Neurotez, Inc.
Neurotez, Inc. a private biotechnology corporation proposes to undertake the clinical development of leptin to further its commercialization as a therapy for Alzheimer’s disease (AD) by leveraging existing data from preclinical and animal studies along with extensive clinical data to proceed with an IND filing. Additional products in the discovery stage are targeting familial AD. AD is the primary cause of cognitive impairment among the elderly. It is estimated that up to 50% of 85 yr olds may have AD and there are currently 5 million with AD in the US alone. For more information, please visit www.neurotez.com
Neurotez, Inc.
Nikolaos Tezapsidis, 908-998-1340
Chief Executive Officer
or
Eugene Oliva, 732-729-6250 ext. 4701
Chief Financial Officer
or
Jane Johnston, 732-729-6250 ext. 4702
Executive Director of Research
